

**REMARKS**

Claims 1-9 and 13-14 are pending in the present application and are presented for examination.


***Restriction Requirement:***

Applicants elect Group I drawn to compounds and pharmaceutical composition of formula I. Claims 1-9 read on Group I.


***Election Requirement:***

The Office Action has also required an election of species. In response, Applicants elect as a single species the compound of Example 15 found on page 38, lines 10-19 of the PCT published application. The compound of Example 15 is:

5-(3-hydroxyphenyl)-1-(quinolin-6-yl) aminoisoquinoline.



The elected species is found in the generic formula 1 of claim 1 as follows:




R<sup>1</sup> is a phenyl group substituted with -OH.

R<sup>2</sup> is quinolinyl.

Applicants note that upon allowance of a generic claim, Applicant will be entitled to consideration of additional species which depend from or otherwise require all the limitations of the allowable generic claim.

Applicants believe that no fees are due in connection with the filing of this paper other than those specifically authorized herewith. However, should any other fees be deemed necessary to affect the timely filing of this paper the Commissioner is hereby authorized to charge such fees to Deposit Account No. 07-1392.

Respectfully submitted,



John L. Lemanowicz  
Attorney for Applicant  
Registration No. 37,380

Date: 13 Oct 08  
GlaxoSmithKline  
Corporate Intellectual Property  
Five Moore Drive  
P.O. Box 13398  
Research Triangle Park, NC 27709-3398  
Phone: 919-483-8247  
Facsimile: 919-483-7988